|
|
Vaccine Detail
|
Retrovector Encoding Mutant Anti-Cyclin G1 Vaccine |
| Vaccine Information |
- Vaccine Name: Retrovector Encoding Mutant Anti-Cyclin G1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007042
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CCNG1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Breast Cancer, Pancreatic Cancer and Sarcoma (NCT00505271). A replication-incompetent, pathotropic, tumor matrix (collagen)-targeted, retroviral vector encoding an N-terminal deletion mutant form of the cyclin G1 gene with potential antineoplastic activity. Under the control of a hybrid long-terminal repeat/cytomegalovirus (CMV) promoter, retrovector encoding mutant anti-cyclin G expresses the mutant cyclin G1 construct, resulting in disruption of tumor cell cyclin G1 activity and decreased cellular proliferation and angiogenesis. This agent preferentially targets collagen of the tumor matrix because of the incorporation of the collagen-binding domain of von Willebrand factor (vWF) on the retrovector surface. Exploiting the collagen-targeting mechanism of vWF permits delivery of the retrovector to tumor sites where angiogenesis and collagen matrix exposure occur (NCIT_C49082).
|
| Host Response |
|
|
| References |
NCIT_C49082: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C49082]
NCT00505271: Safety and Efficacy Study Using Rexin-G for Breast Cancer [https://clinicaltrials.gov/ct2/show/NCT00505271]
|
|
